中国实用医刊
中國實用醫刊
중국실용의간
CENTRAL PLAINS MEDICAL JOURNAL
2015年
12期
69-71
,共3页
郭玮%武东风%杨晓军%李文斌
郭瑋%武東風%楊曉軍%李文斌
곽위%무동풍%양효군%리문빈
培美曲塞%顺铂%非小细胞肺癌%细胞免疫%临床意义
培美麯塞%順鉑%非小細胞肺癌%細胞免疫%臨床意義
배미곡새%순박%비소세포폐암%세포면역%림상의의
Pemetrexed%Cisplatin%Non-small cell lung cancer%Cellular immune%Clinical significance
目的 探讨美曲塞联合顺铂化疗对晚期非小细胞肺癌患者细胞免疫功能的影响及其临床意义.方法 选取2011年2月至2013年2月间于运城市中心医院接受诊断和治疗的晚期非小细胞肺癌患者32例作为观察组,选取同期入院的晚期非小细胞肺癌患者32例作为化疗组,选取同期入院的肺部良性病变患者32例作为对照组,观察记录对照组、化疗组以及观察组患者治疗前后CD3+、CD4+以及NK细胞水平,治疗前后血管内皮生长因子(VEGF)以及基质金属蛋白酶-9(MMP-9)的水平.结果 观察组患者治疗前后CD3+、CD4+以及NK细胞水平均明显低于对照组(t =8.119,6.313,6.135,5.877,7.798,6.850,P均＜0.05);观察组患者治疗后CD3+、CD4+以及NK细胞水平均明显高于化疗组治疗后(t=7.731,5.012,5.897,P均＜0.05);观察组患者治疗后CD3+、CD4+以及NK细胞水平均明显高于治疗前(t=8.159,5.378,6.172,P均＜0.05).观察组患者治疗后VEGF水平为(263.1±37.3) ng/L,显著低于治疗前的(731.2±45.8) ng/L(t=9.984,P＜0.05);观察组患者治疗后MMP-9水平为(903.7±156.2)ng/ml,显著低于治疗前的(1893.5±289.2) ng/ml(t =7.031,P＜0.05).结论 培美曲塞联合顺铂化疗对晚期非小细胞肺癌患者细胞免疫功能具有积极的影响和显著的临床意义,值得在临床中推广应用.
目的 探討美麯塞聯閤順鉑化療對晚期非小細胞肺癌患者細胞免疫功能的影響及其臨床意義.方法 選取2011年2月至2013年2月間于運城市中心醫院接受診斷和治療的晚期非小細胞肺癌患者32例作為觀察組,選取同期入院的晚期非小細胞肺癌患者32例作為化療組,選取同期入院的肺部良性病變患者32例作為對照組,觀察記錄對照組、化療組以及觀察組患者治療前後CD3+、CD4+以及NK細胞水平,治療前後血管內皮生長因子(VEGF)以及基質金屬蛋白酶-9(MMP-9)的水平.結果 觀察組患者治療前後CD3+、CD4+以及NK細胞水平均明顯低于對照組(t =8.119,6.313,6.135,5.877,7.798,6.850,P均＜0.05);觀察組患者治療後CD3+、CD4+以及NK細胞水平均明顯高于化療組治療後(t=7.731,5.012,5.897,P均＜0.05);觀察組患者治療後CD3+、CD4+以及NK細胞水平均明顯高于治療前(t=8.159,5.378,6.172,P均＜0.05).觀察組患者治療後VEGF水平為(263.1±37.3) ng/L,顯著低于治療前的(731.2±45.8) ng/L(t=9.984,P＜0.05);觀察組患者治療後MMP-9水平為(903.7±156.2)ng/ml,顯著低于治療前的(1893.5±289.2) ng/ml(t =7.031,P＜0.05).結論 培美麯塞聯閤順鉑化療對晚期非小細胞肺癌患者細胞免疫功能具有積極的影響和顯著的臨床意義,值得在臨床中推廣應用.
목적 탐토미곡새연합순박화료대만기비소세포폐암환자세포면역공능적영향급기림상의의.방법 선취2011년2월지2013년2월간우운성시중심의원접수진단화치료적만기비소세포폐암환자32례작위관찰조,선취동기입원적만기비소세포폐암환자32례작위화료조,선취동기입원적폐부량성병변환자32례작위대조조,관찰기록대조조、화료조이급관찰조환자치료전후CD3+、CD4+이급NK세포수평,치료전후혈관내피생장인자(VEGF)이급기질금속단백매-9(MMP-9)적수평.결과 관찰조환자치료전후CD3+、CD4+이급NK세포수평균명현저우대조조(t =8.119,6.313,6.135,5.877,7.798,6.850,P균＜0.05);관찰조환자치료후CD3+、CD4+이급NK세포수평균명현고우화료조치료후(t=7.731,5.012,5.897,P균＜0.05);관찰조환자치료후CD3+、CD4+이급NK세포수평균명현고우치료전(t=8.159,5.378,6.172,P균＜0.05).관찰조환자치료후VEGF수평위(263.1±37.3) ng/L,현저저우치료전적(731.2±45.8) ng/L(t=9.984,P＜0.05);관찰조환자치료후MMP-9수평위(903.7±156.2)ng/ml,현저저우치료전적(1893.5±289.2) ng/ml(t =7.031,P＜0.05).결론 배미곡새연합순박화료대만기비소세포폐암환자세포면역공능구유적겁적영향화현저적림상의의,치득재림상중추엄응용.
Objective To investigate the effect of pemetrexed combined with cisplatin on the cellular immune function of patients with advanced non-small cell lung cancer and the clinical significance.Methods From February 2011 to February 2013,32 patients with advanced non-small cell lung cancer were selected as observation group,another 32 patients with advanced non-small cell lung cancer selected as chemotherapy group and 32 patients with benign lung disease were selected as control group.The levels of CD3 +,CD4 +,NK cell,VEGF and MMP-9 were observed.Results The levels of CD3 +,CD4 +,NK cell of the observation group were obviously lower than those of the control group before and after treatment(t =8.119,6.313,6.135,5.877,7.798,6.850,P ＜ 0.05).The levels of CD3 +,CD4 +,NK cell of the observation group after treatment were obviously higher than those after treatment(t =8.159,5.378,6.172,P ＜ 0.05).The levels of C D3+,CD4+,NK cell of the observation group after treatment were obviously higher than those of the chemotherapy group after treatment (t =7.731,5.012,5.897,P ＜0.05).The level of VEGF after treatment was(263.1 ±37.3) ng/L,which was obviously lower than that before treatment (t =9.984,P ＜ 0.05).The level of MMP-9 after treatment was (903.7 ± 156.2) ng/ml,which was obviously lower than that before treatment (t =7.031,P ＜0.05).Conclusions The effect of pemetrexed combined with cisplatin on the patients with advanced non-small cell lung cancer is good,and it deserved promotion.
